News

Nusano Co-Founder Dr. Howard Lewin to Participate in Truist Securities Virtual Radiopharmaceuticals Event

NEW YORK, April 20, 2023 (GLOBE NEWSWIRE) -- Nusano, Inc., a company reshaping the production of cancer-fighting radioisotopes, today announced…

2 years ago

Sensei Biotherapeutics Announces IND Clearance by U.S. FDA Enabling Phase 1 Initiation for SNS-101, a Conditionally Active VISTA-Blocking Antibody

First patient dose in the Phase 1/2 clinical trial expected in mid-2023BOSTON, April 20, 2023 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics,…

2 years ago

Blue Water Announces Acquisition of ENTADFI®, an FDA-Approved Benign Prostatic Hyperplasia Asset

Acquisition Transforms the Company into a Broader Pharmaceutical Company Spanning Multiple Sectors Company Announces Corporate Name Change to Underscore Broader…

2 years ago

Arbutus to Report First Quarter 2023 Financial Results and Provide Corporate Update

WARMINSTER, Pa., April 20, 2023 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging its extensive…

2 years ago

Kane Biotech Announces Distribution Agreement with ProgenaCare Global for its coactiv+™ Antimicrobial Wound Gel

ProgenaCare to commercialize coactiv+™ Antimicrobial Wound Gel in the U.S. wound care marketWINNIPEG, Manitoba, April 20, 2023 (GLOBE NEWSWIRE) --…

2 years ago

The Joint Corp. to Host Conference Call on Thursday, May 4th to Discuss First Quarter 2023 Results

SCOTTSDALE, Ariz., April 20, 2023 (GLOBE NEWSWIRE) -- The Joint Corp. (NASDAQ: JYNT), the nation's largest provider of chiropractic care…

2 years ago

Orphalan announces US commercial launch of Cuvrior™ for the treatment of Wilson disease

Cuvrior™ now available in the US for the treatment of adult patients with stable Wilson disease who are de-coppered and…

2 years ago

ObsEva Announces Change of Central Securities Depositary

Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange GENEVA, Switzerland – April 20, 2023 –…

2 years ago

Tiziana Life Sciences to File Alzheimer’s IND for Intranasal Foralumab in Q2 2023

Application for $3M of non-dilutive funding for Phase 2a Alzheimer’s trial will be submitted in Q2 2023Tiziana guided by FDA…

2 years ago

Microbix Presenting at the 2023 Bloom Burton Conference

MISSISSAUGA, Ontario, April 20, 2023 (GLOBE NEWSWIRE) -- Microbix Biosystems Inc. (TSX: MBX, OTCQX: MBXBF, Microbix®), a life sciences innovator,…

2 years ago